Last reviewed · How we verify

NCT05089747: CIRCAN MAP

CIRculating CANcer MAster-Protocol

Recruiting now Last updated 24 July 2023
What this trial tests

trial testing Blood sampling for biomarker analysis (microRNA, circulating DNA…) in Adult With Solid Cancer in 6,000 participants. Currently enrolling.

Timeline
5 December 2022
Primary endpoint
1 December 2047
1 December 2047

Quick facts

Lead sponsorHospices Civils de Lyon
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment6,000
Start date5 December 2022
Primary completion1 December 2047
Estimated completion1 December 2047
Sites5 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Hospices Civils de Lyon — full company profile →

Who can join

18 and older, any sex, with Adult With Solid Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This exploratory study will focus on the development of the analyses of blood biomarkers to better understand the circulating biomarkers associated with cancer diagnosis, treatment efficacy and progressive disease

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Ambivalent roles of miRNAs in cancer development via modulating tumor-associated innate immune cells.
    Naseri B, Mardi A, Shekari N, Shajari N, et al · · 2025 · PMID 41409584 · DOI 10.34172/bi.31430

Verify or expand the search:

Other Hospices Civils de Lyon trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05089747.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing